In particular, combination of ADI-TRAIL was synergistic with the tubulin inhibitors paclitaxel and docetaxel in the five tested pancreatic cancer cell lines, with irinotecan in all five tested colon cancer cell lines, and with cabozantinib in all four tested renal cell lines. The gene discussed is TNFSF10; the disease is familial pancreatic carcinoma.